Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.39 |
| ▸ | HMGCR | P04035 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9015844 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL56398 | 1.00 | — | — | |
| SCHEMBL1470524 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL730035 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL12500356 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL1470503 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL67396 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL2873944 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL514779 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA | |
| SCHEMBL2877322 | 1.00 | TSHR (0.50) | TSHRTHRBSMN1; SMN2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216649-B2 | Liquid crystal aligning agent, method of producing a liquid crystal alignment film and liquid crystal display device | JSR CORPORATION (JP) | 2012-07-10 | — | — | US | claimed |
| EP-4676912-A2 | COMPOUNDS, COMPOSITIONS, AND METHOD OF INHIBITING TAU PROTEIN AND ALPHA-SYNUCLEIN AGGREGATION | Purdue Research Foundation (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4674946-A1 | NOVEL GENETIC RECOMBINATION MARKER AND USE THEREOF | KAO CORPORATION (JP) | 2026-01-07 | — | — | EP | disclosed |
| EP-4674947-A1 | YEAST MUTANT STRAIN WITH HIGH GLYCOLIPID PRODUCTIVITY | KAO CORPORATION (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4624479-A1 | HYDROSILANE COMPOSITION AND METHOD FOR PREPARING HYDROSILYLATION PRODUCT | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-10-01 | — | — | EP | disclosed |
| US-12390483-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250232174-A1 | MULTIOBJECTIVE COEVOLUTION OF DEEP NEURAL NETWORK ARCHITECTURES | Cognizant Technology Solutions U.S. Corporation (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250232173-A1 | MULTIOBJECTIVE COEVOLUTION OF DEEP NEURAL NETWORK ARCHITECTURES | Cognizant Technology Solutions U.S. Corporation (US) | 2025-07-17 | — | — | US | disclosed |
| CN-120162442-A | Network violence language detection method and system | 北京邮电大学 | 2025-06-17 | — | — | CN | disclosed |
| US-8216649-B2 | Liquid crystal aligning agent, method of producing a liquid crystal alignment film and liquid crystal display device | JSR CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110118422-A1 | LIQUID CRYSTAL ALIGNING AGENT, METHOD OF PRODUCING A LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY DEVICE | JSR CORPORATION (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110068301-A1 | LIQUID CRYSTAL ALIGNING AGENT, METHOD OF PRODUCING A LIQUID CRYSTAL ALIGNMENT FILM AND LIQUID CRYSTAL DISPLAY DEVICE | JSR CORPORATION (JP) | 2011-03-24 | — | — | US | disclosed |
| EP-2182405-A1 | LIQUID CRYSTAL ALIGNING AGENT, METHOD FOR PRODUCING LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY DEVICE | JSR Corporation (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-2182407-A1 | LIQUID CRYSTAL ALIGNING AGENT, METHOD FOR PRODUCING LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY DEVICE | JSR Corporation (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-0553594-A1 | Polymeric thermoplastic materials, comprising 1,2,4-triazolidine-3,5-dione derivatives as stabilisers | CIBA-GEIGY AG (CH) | 1993-08-04 | — | — | EP | disclosed |
| US-5196465-A | Heat resistance | CIBA-GEIGY CORPORATION (US) | 1993-03-23 | — | — | US | disclosed |
| US-4219464-A | Hindered piperidine carboxylic acids, metal salts thereof and stabilized compositions | CIBA-GEIGY CORPORATION (US) | 1980-08-26 | — | — | US | disclosed |
| US-4203890-A | Hindered piperidine carboxylic acids, metal salts thereof and stabilized compositions | CIBA-GEIGY CORPORATION (US) | 1980-05-20 | — | — | US | disclosed |
| US-4101509-A | Hindered piperidine carboxylic acids, metal salts thereof and stabilized compositions | CIBA-GEIGY CORPORATION (US) | 1978-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390483-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | TSHR 3829/4885THRB 2128/4885SMN1; SMN2 83/4885 |
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | TSHR 3829/4885THRB 2128/4885SMN1; SMN2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.